Mary Guckert

6.4k total citations
18 papers, 808 citations indexed

About

Mary Guckert is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Mary Guckert has authored 18 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Organic Chemistry and 7 papers in Oncology. Recurrent topics in Mary Guckert's work include Multiple Myeloma Research and Treatments (6 papers), Nausea and vomiting management (5 papers) and Melanoma and MAPK Pathways (5 papers). Mary Guckert is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Nausea and vomiting management (5 papers) and Melanoma and MAPK Pathways (5 papers). Mary Guckert collaborates with scholars based in United States, Netherlands and Italy. Mary Guckert's co-authors include Vicki Goodman, Jean‐Jacques Grob, Richard Kefford, Dirk Schadendorf, Georgina V. Long, Paolo A. Ascierto, Uwe Trefzer, Ravi K. Amaravadi, Tabea Wilhelm and Anne O’Hagan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Mary Guckert

18 papers receiving 792 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Guckert United States	13	509	462	145	127	93	18	808
Yanmei Xu China	9	736 1.4×	528 1.1×	41 0.3×	27 0.2×	194 2.1×	21	1.0k
Amy Weise United States	19	438 0.9×	530 1.1×	59 0.4×	43 0.3×	102 1.1×	69	946
Arthur Groy United States	6	497 1.0×	279 0.6×	48 0.3×	18 0.1×	78 0.8×	7	696
François Wilhelm United States	16	270 0.5×	264 0.6×	220 1.5×	173 1.4×	90 1.0×	64	796
Ruri Ohki Japan	13	365 0.7×	153 0.3×	64 0.4×	155 1.2×	133 1.4×	18	743
Elisa Sala Italy	17	373 0.7×	435 0.9×	59 0.4×	25 0.2×	134 1.4×	46	842
G Pöch United States	7	464 0.9×	280 0.6×	25 0.2×	30 0.2×	50 0.5×	18	699
Laura A. Pike United States	13	401 0.8×	313 0.7×	60 0.4×	29 0.2×	113 1.2×	26	743
Huiying Zhi United States	12	372 0.7×	127 0.3×	165 1.1×	101 0.8×	119 1.3×	20	684
Kelly E. Fisher United States	4	434 0.9×	288 0.6×	36 0.2×	12 0.1×	80 0.9×	6	599

Countries citing papers authored by Mary Guckert

Since Specialization

Citations

This map shows the geographic impact of Mary Guckert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Guckert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Guckert more than expected).

Fields of papers citing papers by Mary Guckert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Guckert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Guckert. The network helps show where Mary Guckert may publish in the future.

Co-authorship network of co-authors of Mary Guckert

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Guckert. A scholar is included among the top collaborators of Mary Guckert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Guckert. Mary Guckert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

1.

Shen, Fei, William Kevin Kelly, Neeta Pandit‐Taskar, et al.. (2024). Preclinical characterization of human Kallikrein 2 (hK2) as a novel target for the treatment of prostate cancer.. Journal of Clinical Oncology. 42(4_suppl). 202–202. 2 indexed citations

2.

Urtishak, Karen, Gerhardt Attard, Tokuwa Kanno, et al.. (2022). Abstract 4133: High prevalence and heterogeneity of emergence of BRCA reversion mutations at progression on niraparib treatment in BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) patients. Cancer Research. 82(12_Supplement). 4133–4133. 2 indexed citations

3.

Moreau, Philippe, Jonathan L. Kaufman, Heather J. Sutherland, et al.. (2016). Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux. Blood. 128(22). 489–489. 14 indexed citations

4.

Usmani, Saad Z., Meletios Α. Dimopoulos, Andrew Belch, et al.. (2016). Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux. Blood. 128(22). 1151–1151. 22 indexed citations

5.

Plesner, Torben, Hendrik‐Tobias Arkenau, Peter Gimsing, et al.. (2015). Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503). Blood. 126(23). 507–507. 35 indexed citations

6.

Palumbo, Antonio, Meletios Α. Dimopoulos, Donna Reece, et al.. (2015). Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor).. Journal of Clinical Oncology. 33(15_suppl). TPS8609–TPS8609. 6 indexed citations

7.

Plesner, Torben, Hendrik‐Tobias Arkenau, Henk M. Lokhorst, et al.. (2014). Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.. Journal of Clinical Oncology. 32(15_suppl). 8533–8533. 32 indexed citations

8.

Plesner, Torben, Hendrik‐Tobias Arkenau, Henk M. Lokhorst, et al.. (2014). Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. Blood. 124(21). 84–84. 41 indexed citations

9.

Ascierto, Paolo A., David R. Minor, Antoni Ribas, et al.. (2013). Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(26). 3205–3211. 338 indexed citations

10.

Hauschild, Axel, Jean‐Jacques Grob, Lev Demidov, et al.. (2013). An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).. Journal of Clinical Oncology. 31(15_suppl). 9013–9013. 89 indexed citations

11.

Kirkwood, John M., Georgina V. Long, Uwe Trefzer, et al.. (2012). BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).. Journal of Clinical Oncology. 30(15_suppl). 8501–8501. 22 indexed citations

12.

Hauschild, Axel, Jean‐Jacques Grob, Lev Demidov, et al.. (2012). Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF^V600E-mutated melanoma.. Journal of Clinical Oncology. 30(15_suppl). LBA8500–LBA8500. 35 indexed citations

13.

Hauschild, Axel, Jean‐Jacques Grob, Lev Demidov, et al.. (2012). Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF^V600E-mutated melanoma.. Journal of Clinical Oncology. 30(18_suppl). LBA8500–LBA8500. 25 indexed citations

14.

Grunberg, Steven M., Janusz Rolski, Zeba Aziz, et al.. (2009). Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 10(6). 549–558. 47 indexed citations

15.

Herrstedt, Jørn, Zeba Aziz, Fausto Roila, et al.. (2009). Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy. Journal of Clinical Oncology. 27(32). 5363–5369. 60 indexed citations

16.

Strausz, János, Janusz Rolski, Zeba Aziz, et al.. (2008). Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC). Journal of Clinical Oncology. 26(15_suppl). 20585–20585. 10 indexed citations

17.

Herrstedt, Jørn, Janusz Rolski, Rajesh Bandekar, et al.. (2008). Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC). Journal of Clinical Oncology. 26(15_suppl). 9549–9549. 12 indexed citations

18.

Grunberg, Steven M., Zeba Aziz, Jørn Herrstedt, et al.. (2008). Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). Journal of Clinical Oncology. 26(15_suppl). 9540–9540. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact